Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine

Amosy E. M'Koma, David L. Blum, Jeremy L. Norris, Tatsuki Koyama, Dean Billheimer, Saundra Motley, Mayshan Ghiassi, Nika Ferdowsi, Indrani Bhowmick, Sam S. Chang, Jay H. Fowke, Richard M. Caprioli, Neil A. Bhowmick

Research output: Contribution to journalArticlepeer-review

76 Scopus citations


The heterogeneous progression to the development of prostate cancer (PCa) has precluded effective early detection screens. Existing prostate cancer screening paradigms have relatively poor specificity for cancer relative to other prostate diseases, commonly benign prostatic hyperplasia (BPH). A method for discrimination of BPH, HGPIN, and PCa urine proteome was developed through testing 407 patient samples using matrix assisted laser desorption-mass spectrometry time of flight (MALDI-TOF). Urine samples were adsorbed to reverse phase resin, washed, and the eluant spotted directly for MALDI-TOF analysis of peptides. The processing resolved over 130 verifiable signals of a mass range of 1000-5000 m/z to suggest 71.2% specificity and 67.4% sensitivity in discriminating PCa vs. BPH. Comparing BPH and HGPIN resulted in 73.6% specificity and 69.2% sensitivity. Comparing PCa and HGPIN resulted in 80.8% specificity and 81.0% sensitivity. The high throughput, low-cost assay method developed is amenable for large patient numbers required for supporting biomarker identification.

Original languageEnglish (US)
Pages (from-to)829-834
Number of pages6
JournalBiochemical and Biophysical Research Communications
Issue number3
StatePublished - Feb 16 2007


  • BPH
  • PSA
  • Prostate cancer
  • Urine peptide profiling

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine'. Together they form a unique fingerprint.

Cite this